Structure-Function Relationship of Lipoprotein Lipase-mediated Enhancement of Very Low Density Lipoprotein Binding and Catabolism by the Low Density Lipoprotein Receptor
Open accessAbstract
We examined the structure-function relationship of human lipoprotein lipase (hLPL) in its ability to enhance the binding and catabolism of very low density lipoproteins (VLDL) in COS cells. Untransfected COS cells did not bind to or catabolize normal VLDL. Expression of wild-type hLPL by transient transfection enhanced binding, uptake, and degradation of the VLDL (a property of LPL that we call bridge function). Heparin pretreatment and a monoclonal antibody ID7 that blocks LDL receptor-binding domain of apoE both inhibited binding, and apoE2/E2 VLDL from a Type III hyperlipidemic subject did not bind. However, LDL did not reduce 125I-VLDL binding to the hLPL-expressing cells, whereas rabbit beta-VLDL was an effective competitor. By contrast, LDL reduced uptake and degradation of 125I-VLDL to the same extent as excess unlabeled VLDL or beta-VLDL. These data suggest that binding occurs by direct interaction of VLDL with LPL but the subsequent catabolism of the VLDL is mediated by the LDL receptor. Mutant hLPLs that were catalytically inactive, S132A, S132D, as well as the partially active mutant, S251T, and S172G, gave normal enhancement of VLDL binding and catabolism, whereas the partially active mutant S172D had markedly impaired capacity for the process; thus, there is no correlation between bridge function and lipolytic activity. A naturally occurring genetic variant hLPL, S447-->Ter, has normal bridge function. The catalytic center of LPL is covered by a 21-amino acid loo…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The increased levels of plasma LPL following gene transfer may promote lipoprotein clearance both by increasing the rate of lipolysis and exposing the receptor-binding domain of apoE, as well as by direct receptor-mediated clearance mechanisms involving LPL.
“The increased levels of plasma LPL following gene transfer may promote lipoprotein clearance both by increasing the rate of lipolysis and exposing the receptor-binding domain of apoE, as well as by direct receptor-mediated clearance mechanisms involving LPL ( 38,39 ).”
From Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4 (2011) · cites this paper as [38]
Cited by
Sorted by citations
Redox signaling and the MAP kinase pathways
Torres, M., & Forman, H. J. (2003) · BioFactors · doi:10.1002/biof.5520170128 · Cited by 580 · see citing works
T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation
Jackson, S. H., Devadas, S., Kwon, J., Pinto, L. A., & Williams, M. S. (2004) · Nature Immunology · doi:10.1038/ni1096 · Cited by 457 · see citing works
Lipoprotein Lipase S447X: A Naturally Occurring Gain-of-Function Mutation
Rip, J., Nierman, M. C., Ross, C. J., Jukema, J. W., Hayden, M. R., Kastelein, J. J. P., Stroes, E. S. G., & Kuivenhoven, J. A. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000219283.10832.43 · Cited by 157 · see citing works
Vezeridis, A. M., Drosatos, K., & Zannis, V. I. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m008409 · Cited by 11 · see citing works
Fotakis, P., Vezeridis, A., Dafnis, I., Chroni, A., Kardassis, D., & Zannis, V. I. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m048348 · Cited by 4 · see citing works
- Authors
- Salinelli, S., Lo, J.-Y., Mims, M. P., Zsigmond, E., Smith, L. C., & Chan, L.
- Affiliations
- Baylor College of Medicine (US)
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1996-09
- Volume
- 271
- Issue
- 36
- Pages
- 21906-21913
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2026299299
- Cited by
- 153
- References
- 0
- Citations by year
- 2019: 1 · 2018: 1 · 2015: 2 · 2014: 5 · 2013: 2
- FWCI
- 9.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL16512, HL27341, R01HL046860, HL-46860)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein lipase, VLDL, LDL receptor, VLDL catabolism, bridge function, apolipoprotein E, type III hyperlipidemia, catalytic loop, heparin
- MeSH terms
- Animals, Apolipoproteins B, Apolipoproteins E, Binding Sites, Catalysis, Cricetulus, Enzyme-Linked Immunosorbent Assay, Cricetinae, Humans, Lipoprotein Lipase, Lipoproteins, LDL, Lipoproteins, VLDL, Rabbits, Receptors, LDL, Structure-Activity Relationship, Transfection, Point Mutation, Protein Structure, Tertiary, Apolipoprotein B-100
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review